AMED Stock Recent News Amedisys Inc (AMED) 24.79 11/08/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 12:25 AM

Amedisys Inc (AMED) 24.79 $AMED

Amsurg's Q3 Earnings Top on Revenue Growth, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:20AM CST
Amsurg Corp. (AMSG) reported third-quarter 2014 adjusted earnings per share (EPS) of 66 cents from continuing operations.
CHE: 106.93 (-0.26), AMSG: 51.50 (+0.16), RDNT: 8.37 (-1.48), AMED: 24.79 (-0.38)

2014 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide
GlobeNewswire - Wed Nov 05, 10:00AM CST
Amedisys, a leading healthcare at home company (Nasdaq:AMED), today announced that 162 of its care centers across the country have been named to the 2014 HomeCare Elite(TM), a compilation of the top-performing home health agencies in the United States compiled annually by OCS Home Care and DecisionHealth.
NRCIA: 17.05 (+0.04), AMED: 24.79 (-0.38), NRCIB: 34.50 (+0.41)

Can Amedisys (AMED) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:50AM CST
Amedisys could be an interesting play for investors as the stock has a decent short-term momentum and is seeing solid activity on the earnings estimate revision
AMED: 24.79 (-0.38)

Amedisys Up 61.4% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Tue Nov 04, 9:40AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 4 months, Amedisys has returned 61.39% as of today's recent price of $25.83.
AMED: 24.79 (-0.38)

Your Best Stocks Will Be in the Best Industries - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Nov 04, 3:01AM CST
Your Best Stocks Will Be in the Best Industries - Screen of the Week
BCC: 37.43 (-0.17), HNI: 46.59 (-0.03), ALDW: 18.98 (+0.37), AMED: 24.79 (-0.38), FLWS: 8.29 (+0.37)

Is Emerson Electric (EMR) Likely to Miss on Earnings Again? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:51PM CDT
Emerson Electric Co. (EMR), a global technological solutions provider, is set to report fourth-quarter and full-year 2014 results on Nov 4, before the opening bell.
BBRY: 10.53 (+0.26), EMR: 64.86 (+0.19), AMED: 24.79 (-0.38), AAPL: 109.01 (+0.31)

Amedysis Turns Around with Q3 Earnings Beat, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 1:50PM CDT
Following Amedisys' (AMED) promising earnings announcement, the company's stock price surged 16.2% to eventually close at $25.28 yesterday.
AMSG: 51.50 (+0.16), USPH: 39.03 (-1.51), RDNT: 8.37 (-1.48), AMED: 24.79 (-0.38)

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
ACPW: 1.89 (+0.01), ACMP: 62.89 (+1.19), AMAG: 34.95 (+0.83), AMED: 24.79 (-0.38), ACCO: 8.55 (unch)

Amedisys (AMED) Upgraded From Hold to Buy
at The Street - Fri Oct 31, 8:09AM CDT
Amedisys (AMED) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
AMED: 24.79 (-0.38)

Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.06 (-0.03), ABMD: 32.13 (+0.47), BGFV: 12.95 (+0.27), RDCM: 8.80 (+0.12), AMED: 24.79 (-0.38), MRCY: 13.51 (-0.18), OMER: 17.37 (+0.09), ESBF: 18.66 (+0.03), EVOK: 6.70 (+0.08), IQNT: 17.14 (-0.14), KONA: 22.76 (-0.03), TQNT: 22.07 (-0.82), LAKE: 13.29 (+0.42), SAJA: 5.79 (-0.61)

Watch Electronic Arts, SolarWinds, 2 More for Upside Momentum
at The Street - Thu Oct 30, 12:05PM CDT
Big recent moves in these four stocks suggest the likelihood of continued momentum.
SWI: 48.31 (+0.03), ZLTQ: 27.49 (-0.25), EA: 40.94 (+0.14), AMED: 24.79 (-0.38)

Critical Alerts For General Electric, Amedisys Inc, RF Micro Devices, JC Penney and SolarCity Released By InvestorsObserver
PR Newswire - Thu Oct 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GE, AMED, RFMD, JCP and SCTY.
GE: 26.41 (+0.05), SCTY: 50.97 (-0.57), JCP: 7.82 (+0.34), AMED: 24.79 (-0.38), RFMD: 13.23 (-0.53)

Amedisys Inc. (AMED) in Focus: Stock Surges 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:21AM CDT
Amedisys Inc. (AMED) was a big mover last session, as the company saw its shares rise nearly 16% on the day.
AMSG: 51.50 (+0.16), USPH: 39.03 (-1.51), RDNT: 8.37 (-1.48), AMED: 24.79 (-0.38)

Upgrade Alert for Amedisys (AMED)
Comtex SmarTrend(R) - Thu Oct 30, 6:53AM CDT
Amedisys (NASDAQ:AMED) was upgraded from Underperform to Neutral at RW Baird today. The stock closed yesterday at $25.22 on volume of 1.6 million shares, above average daily volume of 269,000. Amedisys (NASDAQ:AMED) is currently priced 31.4% above its average consensus analyst price target of $17.31. The stock should find initial support at its 50-day moving average (MA) of $20.78 and further support at its 200-day MA of $16.87.
AMED: 24.79 (-0.38)

Amedisys beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 9:07AM CDT
BATON ROUGE, La. (AP) _ Amedisys Inc. (AMED) on Wednesday reported net income of $8.4 million in its third quarter.
AMED: 24.79 (-0.38)

Amedisys Reports Third Quarter Financial Results
GlobeNewswire - Wed Oct 29, 6:00AM CDT
Amedisys, Inc. (Nasdaq:AMED), a leading home health and hospice company, today reported its financial results for the three and nine-month periods ended September 30, 2014.
AMED: 24.79 (-0.38)

35.6% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Tue Oct 28, 9:12AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 4 months, Amedisys has returned 35.58% as of today's recent price of $21.70.
AMED: 24.79 (-0.38)

5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Oct 27, 12:00PM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
KN: 19.31 (+0.41), RYAM: 27.97 (-0.13), CLF: 11.17 (+0.63), AMED: 24.79 (-0.38), LOCK: 16.96 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...